A search for evidence of somatic mutations in theNF1 gene. Issue 1 (1st January 2000)

• Record Type: Journal Article
• Authors: John, Alison M; Ruggieri, Martino; Ferner, Ros; Upadhyaya, Meena
• Is Part Of: Journal of medical genetics. Volume 37:Issue 1(2000)
• Page Start: 44
• Page End: 49
• Publication Date: 2000-01-01
• Subjects: neurofibromatosis -- NF1gene -- somatic mutations; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmg.37.1.44
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Neurofibromatosis type I (NF1) is an autosomal dominant disorder affecting 1 in 3000 people. The NF1 gene is located on chromosome 17q11.2, spans 350 kb of genomic DNA, and contains 60 exons. A major phenotypic feature of the disease is the widespread occurrence of benign dermal and plexiform neurofibromas. Genetic and biochemical data support the hypothesis that NF1 acts as a tumour suppressor gene. Molecular analysis of a number of NF1 specific tumours has shown the inactivation of both NF1 alleles during tumourigenesis, in accordance with Knudson's "two hit" hypothesis. We have studied 82 tumours from 45 NF1 patients. Two separate strategies were used in this study to search for the somatic changes involved in the formation of NF1 tumours. First, evidence of loss of heterozygosity (LOH) of the NF1 gene region was investigated, and, second, a screen for the presence of sequence alterations was conducted on a large panel of DNA derived from matched blood/tumour pairs. In this study, the largest of its kind to date, we found that 12% of the tumours (10/82) exhibited LOH; previous studies have detected LOH in 3-36% of the neurofibromas examined. In addition, an SSCP/HA mutation screen identified five novel NF1 germline and two somatic mutations. In a plexiform neurofibroma from an NF1 patient, mutations in both NF1 alleles have been characterised.